Clinical Programs

Our purpose is to make
a difference for patients

Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting immunotherapies for the treatment of cancer. Immatics is sponsoring several clinical trials  to deliver the power of T cells to cancer patients. The purpose of these trials is to develop innovative personalized immunotherapies aimed at targeting a patient’s tumor selectively and effectively.

We have a big goal: overcome the challenges of fighting cancer and bring new therapeutic tools to cancer patients. We will do this with passion and relentless focus to achieve better outcomes for patients.

Active Clinical
Trial Sites:

United States:
The University of Texas MD Anderson Cancer Center – Houston, Texas
Columbia University Irving Medical Center – New York, New York
UPMC Hillman Cancer Center – Pittsburg, Pennsylvania

Europe:
Universitätsklinikum Bonn – Bonn, Germany
Universitätsklinikum Carl Gustav Carus Dresden – Dresden, Germany
Universitätsklinikum Würzburg – Würzburg, Germany

Clinical
Trials

The following three clinical trials are currently open and recruiting patients:

The IMA201-101 trial (NCT03247309) is a first-in-human dose-escalating trial evaluating safety, tolerability and initial signs of clinical efficacy of Immatics’ IMA201 ACTengine® product, which targets melanoma-associated antigen 4 or 8 (MAGEA4/A8) in patients with solid tumors.

Among the range of solid cancer indications, this study is focused on, but not limited to, head and neck squamous cell carcinoma (HNSCC), squamous non-small cell carcinoma (squamous NSCLC) and subtypes of sarcoma due to a high frequency of MAGEA4/8 expression in these tumors.

For more information on this trial, click here

The IMA202-101 trial (NCT03441100) is a first-in-human dose-escalating trial evaluating safety, tolerability and initial signs of clinical efficacy of Immatics’ IMA202 ACTengine® product, which targets melanoma-associated antigen 1 (MAGEA1) in patients with various solid tumors, including NSCLC and hepatocellular carcinoma (HCC).

For more information on this clinical trial, click here

The IMA203-101 trial (NCT03686124) is a first-in-human dose-escalating trial evaluating the safety, tolerability, and initial signs of clinical efficacy of Immatics’ IMA203 ACTengine® product, which targets preferentially expressed antigen in melanoma (PRAME) in patients with solid tumors.

Among a broad range of solid cancer indications, uterine cancer (endometrial cancer and uterine carcinoma), ovarian cancer, melanoma, several subtypes of sarcoma and squamous non-small cell lung cancer are of special interest because PRAME expressed in these tumors with a very high frequency.

For more information on this clinical trial, click here

If you are a patient and interested participating in one of Immatic’s clinical trials, please speak to your treating physician.